Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Clinical trial NCT02436135 · TERMINATED
Trial details
- NCT number
- NCT02436135
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-05
- Primary completion
- 2017-11-20
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.